Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload

Selective SGLT2 inhibition reduces the risk of worsening heart failure and cardiovascular death in patients with existing heart failure, irrespective of diabetic status. We aimed to investigate the effects of dual SGLT1/2 inhibition, using sotagliflozin, on cardiac outcomes in normal diet (ND) and h...

Full description

Bibliographic Details
Main Authors: Sophia L. Young, Lydia Ryan, Thomas P. Mullins, Melanie Flint, Sarah E. Steane, Sarah L. Walton, Helle Bielefeldt-Ohmann, David A. Carter, Melissa E. Reichelt, Linda A. Gallo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Physiology
Subjects:
energy expenditure
energy intake
proximal tubular cell damage
cardiac hypertrophy
cardiovasclar disease
heart failure
Online Access:https://www.frontiersin.org/articles/10.3389/fphys.2021.738594/full

Internet

https://www.frontiersin.org/articles/10.3389/fphys.2021.738594/full

Similar Items